文献速递脑血管病外科

破裂脑动静脉畸形接受亚急性治疗患者的再出血风险:单中心系列及系统文献综述

Risk of Rebleeding in Patients Suffering From Ruptured Brain Arteriovenous Malformations Undergoing Subacute Treatment: A Single-Center Series and Systematic Review of the Literature.
PubMed 文献 · World Neurosurg · 2019-11-01

本研究纳入2000至2018年在本机构因破裂脑动静脉畸形(BAVM)计划在初次出血至少4周后治疗的患者55例,均无早期再出血;将本组数据与文献数据合并后共166例接受亚急性治疗,其中1例(0.6%)在初次破裂后130天恢复期发生再出血。系统综述与单中心系列显示亚急性治疗后再出血率为0.6%。

要点

  • 本机构55例破裂BAVM患者亚急性治疗前均无早期再出血。
  • 合并文献数据共166例,恢复期再出血1例(0.6%),发生于初次破裂后130天。
  • 严格治疗流程筛选高再出血风险患者后,破裂BAVM亚急性治疗似乎安全。

核心结论

  • 本单中心系列与系统综述显示,接受亚急性治疗的破裂BAVM患者再出血率为0.6%。
  • 在应用严格治疗流程筛选出再出血高风险患者后,破裂BAVM的亚急性治疗似乎安全。

研究设计与样本

  • 单中心系列纳入2000至2018年在本机构因破裂BAVM计划在初次出血至少4周后治疗的患者55例,均在神经康复及出血所致脑肿胀消退后行亚急性治疗。
  • 同时对当代同行评议文献中关于破裂BAVM治疗策略的文献进行系统综述,并将本组数据与文献数据合并分析,共166例接受亚急性治疗。
  • 主要结局定义为因破裂BAVM再出血导致的治疗失败,即先前被判定适合亚急性治疗的患者发生再出血。

主要发现

  • 本机构55例患者中,无患者在确定性BAVM治疗前发生早期再出血。
  • 合并文献数据共166例接受亚急性治疗的患者中,1例(0.6%)在初次BAVM破裂后130天恢复期发生再出血。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The optimal timing for treatment of ruptured brain arteriovenous malformation (BAVM) is still controversial. The present study aims to determine safety of subacute BAVM management in clinically stable patients by identifying the rate of rebleeding. METHODS: Patients presenting from 2000 to 2018 with ruptured BAVM who were scheduled for BAVM treatment at least 4 weeks after initial hemorrhage were included in the present study. After neurological rehabilitation of the patient and decreased hemorrhage-induced brain swelling, subacute treatment for the ruptured BAVM was carried out. Primary outcome of the present series was defined as treatment failure resulting from rehemorrhage caused by the ruptured BAVM in patients previously labeled eligible for subacute BAVM treatment. Additionally, we performed a systematic review of the contemporary peer-reviewed literature concerning treatment strategy in patients with ruptured BAVM. RESULTS: Fifty-five patients suffering from ruptured BAVM were considered eligible for subacute BAVM treatment at our institution. No patient suffered from early rebleeding before definitive BAVM treatment in our institutional group. Our own patient data were then pooled with data from the literature, resulting in 166 patients suffering from ruptured BAVM who underwent subacute BAVM treatment. Of these, 1 patient (0.6%) suffered from rehemorrhage during the recovery period 130 days after initial BAVM rupture. CONCLUSIONS: The present series and systematic review revealed a rehemorrhage rate of 0.6% in patients suffering from ruptured BAVM who underwent subacute treatment. Therefore, subacute treatment of patients with ruptured BAVM seems safe after application of rigorous treatment algorithms to sort out patients with higher risk for rehemorrhage.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Schuss P, Hadjiathanasiou A, Ilic I, et al. Risk of Rebleeding in Patients Suffering From Ruptured Brain Arteriovenous Malformations Undergoing Subacute Treatment: A Single-Center Series and Systematic Review of the Literature. World Neurosurg. 2019. PMID: 31678312. doi:10.1016/j.wneu.2019.10.148

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。